Q. I developed severe depression while taking Repatha, the injectable cholesterol lowering drug. It took me a horrible nine months to realize the drug was making me suicidal. If I wasn’t sleeping, I ...

Q. I developed severe depression while taking Repatha, the injectable cholesterol-lowering drug. It took me a horrible nine months to realize the drug was making me suicidal. If I wasn’t sleeping, I ...

DURHAM, N.C., November 25, 2025--(BUSINESS WIRE)--Target RWE, a leader in advancing modern evidence generation for complex clinical and regulatory challenges, today announced the presentation of ...

Amgen has reported positive results from its phase 3 VESALIUS-CV trial, which demonstrated that Repatha (evolocumab) significantly reduced the risk of first-time major adverse cardiovascular events ...

Most stand-alone Medicare Part D prescription drug plans and Medicare Advantage plans that include drug coverage cover Repatha, an injectable medication for high cholesterol and cardiovascular disease ...

Adding Amgen's cholesterol drug Repatha to standard therapy reduced major cardiovascular events by 25% for at-risk patients who have never had a heart attack or stroke, according to results from a ...

Patients receiving Repatha achieved a median LDL cholesterol level of 45 mg/dL compared to 109 mg/dL in the placebo group. "Repatha has once again demonstrated its ability to protect patients from the ...

THOUSAND OAKS, Calif., Nov. 8, 2025 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced detailed results from the Phase 3 VESALIUS-CV clinical trial, which showed that Repatha ® (evolocumab) achieved ...

Amgen announced that new data from its cardiovascular portfolio, including late-breaking results from the phase 3 VESALIUS-CV clinical trial of Repatha (evolocumab), will be presented at the American ...